KAHR Medical, the developer of novel drugs for the treatment of cancer and autoimmune diseases, will raise $2.6 million at a pre-investment valuation of $11 million. KAHR Medical is a portfolio company in which Hadasit Bio-Holdings, a publicly traded portfolio of biotech companies based on intellectual property developed by the Hadassah University Hospital, and Sanofi hold approximately 70% and 20% respectively. Thomas Eldered, co-owner of Recipharm, will invest $2 million and hold approximately 15% of the company. The pharmaceutical company Sanofi will maintain its current holdings with an investment of $500,000. Hadasit Bio-Holdings will invest an additional $100,000 and reduce its holding in the company to approximately 55%.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments